Randomized Phase III Trial of Avatrombopag, a Novel Oral Thrombopoietin Receptor Agonist, in Previously Treated Chronic ITP

December 9-12, 2017; Atlanta, Georgia
Cumulative duration of platelet response ≥ 50 x 109/L without rescue therapy was superior with avatrombopag vs placebo.
Format: Microsoft PowerPoint (.ppt)
File Size: 254 KB
Released: December 15, 2017

Acknowledgements

This activity is supported by educational grants from
Novartis Pharmaceuticals Corporation

Related Content

Experts highlight key studies being presented at the upcoming 2021 ESMO Congress in this commentary from Clinical Care Options (CCO)

person default Eva Ciruelos, MD, PhD Karim Fizazi, MD, PhD Eric Van Cutsem, MD, PhD person default Vamsidhar Velcheti, MD Released: September 15, 2021

Downloadable slideset updated with highlights of key gynecologic oncology studies presented at conferences throughout 2021, from Clinical Care Options (CCO)

Jubilee Brown, MD Melissa M. Hardesty, MD, MPH person default Alexandra Leary, MD, PhD Domenica Lorusso, MD, PhD Ursula Matulonis, MD David Scott Miller, MD, FACOG, FACS Released: September 15, 2021

Safety and efficacy analysis of larotrectinib in TRK fusion–positive lung cancer, from WCLC 2021 as reported by Clinical Care Options (CCO)

Released: September 15, 2021

Subgroup analysis of IMower010 trial evaluating adjuvant atezolizumab vs best supportive care in patients with resected stage IB-IIIA NSCLC after adjuvant chemotherapy, from WCLC 2021 as reported by Clinical Care Options (CCO)

Released: September 15, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue